EPIDEMIOLOGY AND SEROLOGY OF GYNAECOLOGICAL NEOPLASMS

IN MALAYSIA

A Dissertation Submitted to the University of Malaya in Partial Fulfilment of the
Degree of Master of Philosophy

NOR AZLINA ABD. AZIZ

INSTITUTE OF POSTGRADUATE STUDIES AND RESEARCH
UNIVERSITY OF MALAYA

1998
ABSTRACT

A total of 789 cases of gynaecological neoplasms were recorded during the nine-year period from 1985 to 1993 at the Radiotherapy Unit, General Hospital Kuching, Sarawak, Malaysia. In the present study, the patterns and frequencies of four different sites of gynaecological neoplasms, namely, cervix, ovary, endometrium and vulva/vagina were analysed in the various age and ethnic groups. The highest frequency of gynaecological neoplasms occurred among the Chinese (42.6%) followed by the Ibans (21.9%), the Malays (19.4%) and the other Indigenous Groups (15.2%). All ethnic groups except the Indigenous Groups showed similar pattern of gynaecological neoplasms. The leading cancer site is the cervix, followed by the endometrium, the ovary and vulva/vagina. Among the Indigenous Groups, ovarian cancer comes second after the cervix. The age distribution of the patients showed an increasing number of patients with increasing age and all gynaecological neoplasms were predominant in age groups above 40 years. However, among patients below the age of 40 years, endometrial cancer showed a higher percentage compared to the others. The age standardised rate (ASR) for cervical cancer in Sarawak was 9.9. The Chinese (15.5) and the Ibans (10.7) appeared to have much higher ASR than the Malays (6.3) and the other Indigenous groups (5.4).

The increased risk of cervical neoplasia with seropositivity against multiple viral infections has been reported in several studies. In the present study, the seroepidemiological association of human papillomavirus (HPV), human herpes
simplex virus II (HSV-II), human cytomegalovirus (CMV), Epstein-Barr virus (EBV) and carcinoma of the cervix were performed. Sera from 69 cases of cervical cancer attending the Gynaecology Clinic, Hospital Kuala Lumpur and sera from 44 normal pregnant women attending the Antenatal Clinic, Hospital Kuala Lumpur were screened for HPV, HSV-II, CMV and EBV antibodies. The IgG, IgA and IgM antibodies were measured against HPV type 16 using the enzyme-linked immunosorbent assay (ELISA). For CMV and HSV-II, only the IgG antibodies were measured using ELISA. The IgG and IgA antibodies against EBV viral capsid antigen (VCA) and IgG against EBV early antigen (EA) were measured using the immunofluorescence assay. For the antibodies against HPV 16 E7 protein, cervical carcinoma cases were 23.2% IgG positive, 27.5% IgA positive, 13.0% IgG and IgA positive, and 56.5% IgM positive. The normal pregnant women showed similar pattern where 15.6% were IgG positive, 15.6% IgA positive, 3.0% IgG and IgA positive, and 62.5% IgM positive. Both cervical carcinoma patients and normal pregnant women showed a very high prevalence of IgG antibody to HSV-II i.e. 95.6% and 84.0% respectively. The IgG antibody prevalence to EBV-VCA were also found to be very high in cervical carcinoma cases (88.4%) and normal pregnant women (95.4%). The IgG antibody prevalence to CMV was found to be higher in cervical carcinoma cases (98.6%) than in normal pregnant women (20.4%). In the assessment of antibody prevalence according to their HPV seropositive and seronegative status, both cervical cancer patients and normal pregnant women have high prevalence of HSV-2 and CMV infection regardless of their HPV seropositivity status. However, the prevalence for the various EBV-associated antibodies among HPV seropositive cervical carcinoma
cases were higher compared to HPV seronegative cases. From the results obtained, there seemed to be no correlation between HSV-II or CMV infection and HPV positivity, but there seemed to be a positive correlation between EBV infection and HPV infection. The results obtained suggest that EBV in association with HPV may play a role in the carcinogenesis of cervical cancer.
ABSTRAK


Banyak kajian yang telah melaporkan peningkatan risiko barah serviks dengan seropositiviti terhadap jangkitan virus berbilang. Dalam penyelidikan ini, satu kajian
hubungan seroepidemiologi karsinoma serviks dengan virus papilloma manusia (HPV), virus herpes simplex manusia jenis II (HSV-II), 'cytomegalovirus’ manusia (CMV) dan virus Epstein- Barr (EBV) telah dijalankan. Penyaringan antibody-antibody terhadap HPV, HSV-II, CMV dan EBV telah dilakukan ke atas 69 sampel serum daripada pesakit karsinoma serviks yang mengunjungi Klinik Ginekologi, Hospital Kuala Lumpur dan 44 contoh serum daripada wanita normal yang hamil yang mengunjungi Klinik Antenatal, Hospital Kuala Lumpur. Antibodi IgG, IgA dan IgM terhadap HPV-16 disukat menggunakan ELISA, manakala bagi CMV dan HSV-II hanya antibody IgG sahaja yang disukat menggunakan ELISA. Antibodi IgG dan IgA terhadap EBV-VCA dan antibodi IgG terhadap EBV-EA disukat menggunakan kaedah cerakinan imunofluoresen. Bagi antibodi-antibodi terhadap protein HPV 16 E7, di kalangan pesakit karsinoma serviks, didapati 23.2% adalah positif terhadap IgG, 27.5% positif terhadap IgA, 13.0% positif terhadap IgG dan IgA, dan 56.5% positif terhadap IgM. Bagi wanita hamil, pola yang sama juga ditunjukkan iaitu 15.6% adalah positif terhadap IgG, 15.6% juga positif terhadap IgA, 3.0% positif terhadap IgG dan IgA, dan 62.5% positif terhadap IgM. Pesakit karsinoma serviks dan wanita hamil menunjukkan prevalens antibodi IgG yang tinggi terhadap HSV-II iaitu 95.6% dan 84.0% masing-masing. Prevalens antibodi IgG yang tinggi terhadap EBV-VCA juga ditunjukkan oleh pesakit karsinoma serviks (88.4%) dan wanita hamil (95.4%). Prevalens antibodi IgG terhadap CMV di kalangan pesakit karsinoma serviks (98.6%) adalah lebih tinggi daripada wanita hamil (20.4%). Pesakit karsinoma serviks dan wanita hamil yang normal juga menunjukkan prevalens antibodi yang tinggi terhadap jangkitan HSV-II dan CMV tidak kira sama ada ia seropositif atau seronegatif
terhadap HPV. Namun demikian, pesakit karsinoma serviks yang seropositif terhadap HPV menunjukkan prevalens yang tinggi terhadap pelbagai antibodi-antibodi EBV berbanding pesakit yang seronegatif terhadap HPV. Dari hasil penyelidikan ini, tiada kemungkinan terdapatnya kaitan di antara jangkitan HSV-II atau CMV dengan positiviti HPV, tetapi ada kemungkinan EBV mempunyai kaitan dengan jangkitan HPV. Hasil penyelidikan yang didapati mengesyorkan bahawa EBV bersama HPV mungkin memainkan peranan dalam karsinogenesis barah serviks.
ACKNOWLEDGEMENTS

I acknowledge with sincere appreciation the guidance and support of my supervisor, Dr. Norhanom Abdul Wahab, throughout the entire course of this study. I would also like to express my gratitude to Associate Professor Abdul Aziz Yahya (Hospital Kuala Lumpur) for his assistance in providing the sera samples used in this study. I would also like to thank Hospital Umum Kuching, Sarawak for cooperating in providing the data for the epidemiological studies.

I am also grateful to Dr. J. Dillner for the gift of the synthetic peptide, HPV 16 E7 ORF number 5 and Dr. D.V. Ablashi for the gift of Raji and P3HR-1 cell lines.

My sincere appreciation also goes to Kak Yati and Anil for their constant support and advice, Afidah, Ashril and Rakesh for their technical assistance and Nirmala for collecting the samples. I would also like to thank my friends, Kak Ipah, Ayu, Cah, Zu, Rakesh, Subra and Vim for their friendship and support. My special appreciation also goes to my best friend, Mick and family.

Last but not least, I would like to acknowledge my beloved husband, Zainal Abidin and my children, Ahmad Nazrin and Anis Syahira for their patience and unfailing moral support.

The work was funded by the University of Malaya (Vote F Scheme) and Ministry of Science, Technology and Environment, Malaysia (Grant no. 3/092/01(27)).
TABLE OF CONTENTS

ABSTRACT i
ABSTRAK iv
ACKNOWLEDGEMENTS vii
TABLE OF CONTENTS viii
LIST OF ABBREVIATIONS xii
LIST OF TABLES xv
LIST OF FIGURES xvii

CHAPTER 1 INTRODUCTION 1

CHAPTER 2 LITERATURE REVIEW 7

2.1 Cervical Neoplasms 7
2.1.1 Epidemiology 8
2.1.2 Aetiology 11
2.1.2.i Virus 11
2.1.2.i.a Human Papillomavirus 11
2.1.2.i.b Human Herpes Simplex Virus 15
2.1.2.i.c Epstein-Barr Virus 16
2.1.2.i.d Human Cytomegalovirus 18
2.1.2.ii Oncogenes 18
2.1.2.iii Marital and Sexual Factors 19
2.1.2.iv Menstrual or Reproductive Factors 20
2.1.2.v Male Sex Behaviour 20
2.1.2.vi Cigarette Smoking 21
2.1.2.vii Oral Contraceptives 21
2.1.2.viii Dietary Factors 22
2.1.3 Classification and Staging 22
2.1.4 Diagnosis 22
2.1.5 Clinical Symptoms 24
2.1.6 Treatment and Management 24
2.1.6.i Microinvasive Carcinoma/Carcinoma in situ 24
2.1.6.ii Invasive Carcinoma 24
2.1.6.iii Special Circumstances 25

2.2 Ovarian Cancer 26
2.2.1 Epidemiology 26
2.2.2 Aetiology 27
2.2.2.i Virus 27
2.2.2.ii Oncogenes 27
2.2.2.iii Reproductive and Hormonal Effect 29
2.2.2.iv Oral Contraceptives 29
2.2.2.v Family History 30
2.2.2.vi Molecular Genetic Changes 31
2.2.2.vii Blood Groups 32
2.2.2.viii Environmental Factors 32
2.2.3 Classification and Staging 33
2.2.4 Clinical Symptoms 33
2.2.5 Diagnosis 34
2.2.6 Treatment and Management 35
2.2.6.1 Surgery 35
2.2.6.ii Adjuvant Therapy 35
2.2.6.iii Hormonal Therapy 36

2.3 Endometrial Cancer 37
2.3.1 Epidemiology 37
2.3.2 Aetiology 38
2.3.2.i Socioeconomic Factors 38
2.3.2.ii Anthropometric Variables 38
2.3.2.iii Reproductive and Hormonal Factors 39
2.3.2.iv Medical History 40
2.3.2.v Dietary Factors 40
2.3.2.vi Estrogen Replacement Therapy 40
2.3.2.vii Oral Contraceptives 41
2.3.2.viii Cigarette Smoking 41
2.3.3 Classification and Staging 41
2.3.4 Clinical Symptoms 43
2.3.5 Diagnosis 43
2.3.6 Treatment and Management 44

2.4 Cancer of the Vulva and Vagina 46
2.4.1 Cancer of the Vulva 46
2.4.2 Cancer of the Vagina 46
2.4.3 Epidemiology 47
2.4.4 Aetiology 47
2.4.4.i Social Factors 47
2.4.4.ii Obesity and Reproductive Factors 48
2.4.4.iii Viral Factor 48
2.4.5 Classification and Staging 48
2.4.6 Clinical Symptoms 50
2.4.7 Diagnosis 50
2.4.8 Treatment 50

CHAPTER 3 MATERIALS AND METHODS 51

3.1 EPIDEMIOLOGY OF GYNAECOLOGICAL NEOPLASMS 51
3.1.1 Collection of Epidemiological Data 51
3.1.2 Analysis of Data 51
3.2 SEROLOGY OF CERVICAL CARCINOMA

3.2.1 Collection of sera samples

3.2.2 Detection of IgA, IgG and IgM Antibodies Against HPV Type 16

3.2.2.i Antigen Coating

3.2.2.ii Blocking of Plates

3.2.2.iii Detection of Antibodies

3.2.3 Detection of IgG Antibody to CMV and HSV-II

3.2.4 Cell Cultures and Maintenance

3.2.4.i Cell Lines

3.2.4.ii Revival of Cells

3.2.4.iii Maintenance of Cells

3.2.4.iv Cryopreservation of Cells

3.2.5 Detection of IgA and IgG Antibodies to EBV-VCA and IgG Antibody to EBV-EA

3.2.5.i Enhancement of EBV Antigen Expression

3.2.5.i.a VCA Expression in P3HR-1

3.2.5.i.b EA Expression in Raji

3.2.5.ii Harvesting of Cells

3.2.5.iii Indirect Immunofluorescence Assay

CHAPTER 4 RESULTS

4.1 EPIDEMIOLOGY OF GYNAECOLOGICAL NEOPLASMS

4.1.1 Incidence of gynaecological neoplasms in Sarawak

4.1.2 Most frequent gynaecological neoplasms in Sarawak

4.1.3 Incidence of gynaecological neoplasms in Sarawak with respect to age

4.1.4 Incidence of gynaecological neoplasms in Sarawak with respect to ethnic group

4.1.5 Incidence of gynaecological neoplasms in Sarawak with respect to ethnic group and cancer sites

4.1.6 Ethnic composition with respect to cancer sites

4.1.7 Incidence of cervical neoplasm in Sarawak

4.1.8 Incidence of cervical neoplasm in Sarawak with respect to age

4.2 SEROLOGY OF CERVICAL CARCINOMA

4.2.1 Seroprevalence of HPV 16 E7 in cervical carcinoma patients and normal pregnant women

4.2.2 Seroprevalence of HSV-II and CMV in cervical carcinoma patients and normal pregnant women

4.2.3 Seroprevalence of EBV-associated antibody titres in cervical carcinoma patients and normal pregnant women

4.2.4 Seroprevalence of HSV-II, CMV and EBV in HPV-seropositive and HPV-seronegative cervical carcinoma patients
4.2.5 Seroprevalence of HSV-II, CMV and EBV in HPV-seropositive and HPV-seronegative normal pregnant women 88

CHAPTER 5 DISCUSSION 90

5.1 EPIDEMIOLOGY OF GYNAECOLOGICAL NEOPLASMS IN SARAWAK 90

5.2 SEROEPIDEMIOLOGY OF HPV 16, HSV-II, CMV AND EBV ANTIGEN IN CERVICAL CARCINOMA 100
5.2.1 Seroprevalence of HPV 16 E7 100
5.2.2 Seroprevalence of HSV-II 103
5.2.3 Seroprevalence of EBV 106
5.2.4 Seroprevalence of CMV 107
5.2.5 Seroprevalence of HSV-II, CMV and EBV in cervical carcinoma cases according to HPV seropositivity status 108

CONCLUSION 110
REFERENCES 112
APPENDIX 141
LIST OF ABBREVIATIONS

%  percentage
°C  degree centigrade
µ  micron
µg  microgramme
µl  microlitre
AP  alkaline phosphatase
ASR  age standardized rate
BL  Burkitt’s lymphoma
BSO  bilateral salpingo-oophorectomy
CIN  cervical intrepithelial neoplasm
CMV  cytomegalovirus
CO₂  carbon dioxide
CT  computed tomography
D & C  dilatation & curettage
DMSO  dimethyl sulfoxide
DNA  deoxyribonucleic acid
EA  early antigen
EBNA  Epstein-Barr virus nuclear antigen
EBV  Epstein-Barr virus
ELISA  enzyme-linked immunosorbent assay
FCS
foetal calf serum

FIGO
International Federation of Gynaecology and Obstetrics

g
gramme

GMT
geometric mean titre

h
hour

HD
Hodgkin's disease

HKL
Hospital Kuala Lumpur.

HPV
human papillomavirus

HRT
hormon replacement therapy

HSV
herpes simplex virus

IE
immediate early

LCL
lymphoblastoid cell lines

LMP
latent membrane protein

LOH
loss of heterozygosity

LS
lamb serum

min
minute

ml
millilitre

ng
nanogramme

nm
nanometre

NaOH
sodium hydroxide

NPC
nasopharyngeal carcinoma

ORF
open reading frame
PAC  cisplatin Andriamycin-cyclophosphomide
PBS  phosphate buffered saline
PBS-T phosphate buffered saline-tween
rpm  revolution per minute
RT  room temperature
SHBG  sex hormone binding globulin
TAH  total abdominal hysterectomy
TPA  12-0-tetradecanoyl phorbol-13-acetate
TSG  tumour suppressor gene
VCA  viral capsid antigen
## LIST OF TABLES

<table>
<thead>
<tr>
<th>Tables</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>The percentage of incidence and their ASR of gynaecological neoplasms in developed countries and Asia</td>
<td>2</td>
</tr>
<tr>
<td>1.2</td>
<td>Ten most common cancer among women reported in the Penang Cancer Registry (1996) and their age standardized rates.</td>
<td>3</td>
</tr>
<tr>
<td>2.1</td>
<td>Major clinical association of genital-tract and other mucosal HPVs</td>
<td>13</td>
</tr>
<tr>
<td>2.2</td>
<td>Functions assigned to the papillomavirus open-reading frames</td>
<td>14</td>
</tr>
<tr>
<td>2.3</td>
<td>The International Federation of Gynaecology and Obstetrics (FIGO) staging definitions for carcinomas of the cervix</td>
<td>23</td>
</tr>
<tr>
<td>2.4</td>
<td>The FIGO staging definitions for carcinomas of the ovary</td>
<td>33</td>
</tr>
<tr>
<td>2.5</td>
<td>The FIGO staging of carcinomas of the corpus uteri (endometrium)</td>
<td>42</td>
</tr>
<tr>
<td>2.6</td>
<td>Adjuvant therapy options for endometrial cancer patient with high-risk tumours</td>
<td>44</td>
</tr>
<tr>
<td>2.7</td>
<td>The FIGO staging definitions for the carcinomas of the vulva</td>
<td>49</td>
</tr>
<tr>
<td>2.8</td>
<td>The FIGO staging definitions for carcinomas of the vagina</td>
<td>49</td>
</tr>
<tr>
<td>4.1</td>
<td>The incidence of four sites of gynaecological neoplasms among different ethnic groups in Sarawak from 1985 to 1993</td>
<td>65</td>
</tr>
<tr>
<td>4.2</td>
<td>Age first appeared and peak incidence of four cancer sites of gynaecological neoplasms in Sarawak</td>
<td>70</td>
</tr>
<tr>
<td>4.3</td>
<td>Incidence of gynaecological neoplasms in Sarawak below and above the age 40 years</td>
<td>70</td>
</tr>
<tr>
<td>4.4</td>
<td>The incidence and age standardized rate for cervical cancer in Sarawak (1993)</td>
<td>83</td>
</tr>
<tr>
<td>4.5</td>
<td>Seroprevalence of HPV 16 E7 in cervical carcinoma patients and normal pregnant women</td>
<td>84</td>
</tr>
</tbody>
</table>
4.6 Seroprevalence of HSV-II and CMV in cervical carcinoma patients and normal pregnant women

4.7 Seroprevalence of EBV-associated antibodies in cervical carcinoma patients and normal pregnant women

4.8 Seroprevalence of HSV-II, CMV and EBV in HPV-seropositive and HPV-seronegative cervical carcinoma patients

4.9 Seroprevalence of HSV-II, CMV and EBV in HPV-seropositive and HPV-seronegative normal pregnant women
<table>
<thead>
<tr>
<th>Figures</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Population of Sarawak in 1996.</td>
<td>6</td>
</tr>
<tr>
<td>4.1</td>
<td>Annual incidence of gynaecological neoplasms in Sarawak, Malaysia (1985 - 1993)</td>
<td>66</td>
</tr>
<tr>
<td>4.2</td>
<td>Most frequent gynaecological neoplasms in Sarawak</td>
<td>67</td>
</tr>
<tr>
<td>4.3</td>
<td>Incidence of gynaecological neoplasms with respect to age (years) in Sarawak (1985 - 1993)</td>
<td>69</td>
</tr>
<tr>
<td>4.4</td>
<td>Frequency of gynaecological neoplasms in Sarawak with respect to ethnic group</td>
<td>72</td>
</tr>
<tr>
<td>4.5</td>
<td>Crude incidence of gynaecological neoplasms in Sarawak with respect to ethnic groups for years 1985 to 1993</td>
<td>73</td>
</tr>
<tr>
<td>4.6</td>
<td>Most frequent gynaecological neoplasms in four major ethnic groups in Sarawak</td>
<td>76</td>
</tr>
<tr>
<td>4.7</td>
<td>Ethnic composition in four sites of gynaecological neoplasms in Sarawak</td>
<td>79</td>
</tr>
<tr>
<td>4.8</td>
<td>Crude incidence of cervical neoplasm in Sarawak with respect to ethnic groups for years 1985 to 1993</td>
<td>81</td>
</tr>
<tr>
<td>4.9</td>
<td>Frequency of cervical neoplasm in Sarawak with respect to age and ethnic group</td>
<td>82</td>
</tr>
</tbody>
</table>